Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAESAR: Candesartan/HCT vs Candesartan in Hypertension
NCT00621153Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2008
- Primary completion
- Mar 2009
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hypertension (HTN) comparing Candesartan Monotherapy with Candesartan/HCT Combination (2 arms). Primary endpoint: Changes in Mean Sitting Diastolic Blood Pressure From Baseline After 4 Weeks of Therapy. Started Feb 2008; status: completed.
02
Drugs
candesartan cilexetilhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00621153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621153.